A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma

This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to severe asthma. The study consists of three periods, including an up to 4-week screening period, a 52-week double-blind randomized treatment period, and a 12-week safety follow-up period.

NCT Number	NCT07372287
Lead Sponsor	CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Conditions	Moderate to Severe Asthma
Enrollment	230 participants
Start Date	2026-01-23
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-28